Haemoglobin A1c Testing Devices Market Size, Share & Industry Analysis, By Type (Assay (Immunoassay,Direct Enzymatic Assay), Chromatography (Reversed phase HPLC, Ion-exchange chromatography, Boronate affinity chromatography) Others), By End User (Hospitals, Clinics, Home Care Settings, Others) and Regional Forecast, 2024-2032

In June 2019, Abbott launched the Afinion HbA1c assay, which is the first and only rapid point-of-care test to aid in the diagnosis of diabetes. Haemoglobin A1c (HbA1c) test is highly recommended to determine the risk of developing diabetes. The test plays substantial role in taking diabetes treatment and monitoring decisions. However, it has diagnostic limitations for gestational diabetes, diabetes in children, or if a person has anaemia or any other blood disorder. Haemoglobin A1c levels between 5.7% and 6.4% indicates the person has a higher chance of getting diabetes, and the levels of 6.5% and higher indicates the person has diabetes. Various methods for measuring HbA1c include ion-exchange chromatography, electrophoretic methods, mass spectroscopy, reversed-phase HPLC, and electrospray iontophoresis.

The rising prevalence of diabetes is primarily expected to drive the grwoth of the haemoglobin A1c testing devices market during the forecast period. Moreover, increasing emphasis on preventive care coupled with higher accuracy offered by HbA1c testing devices for diabetes diagnosis is anticipated to offer significant growth opporunity for the market. However, the high cost of the devices and lack of product awareness in emerging nations is projected to hamper the market growth during the forecast period.

Key Players Covered:

Some of the major companies that are present in the haemoglobin A1c testing devices market are F. Hoffmann-La Roche AG, Abbott, Siemens Healthcare GmbH, Beckman Coulter, Inc., Danaher, Bayer AG, Bio-Rad Laboratories, Inc. Thermo Fisher Scientific Inc., Trinity Biotech, and others.

Key Insights

• Prevalence of diabetes for key countries or key regions,2018


• New product launches in haemoglobin a1c testing devices market


• Technological advancements in global haemoglobin a1c testing devices market


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis:

North America is anticipated to dominate the global hemoglobin A1c testing devices market owing to the rising prevalence of diabetic patients and developed healthcare infrastructure. For instance, according to study conducted by International Diabetes Federation in 2017, an estimated 45.9 Mn adults were living with diabetes in North America, representing the regional prevalence of around 13.0% of the population. Higher product awareness and adoption of tests in countries such as Germany, France, and UK are expected to drive the growth of the market in Europe.

On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. Certain factors such as evolving healthcare infrastructure in nations such as China and India combined with exponentially increasing prevalence of diabetes is projected to drive the growth of the hemoglobin A1c testing devices market in Asia Pacific. Latin America and Middle East America are also expected to have a substantial growth in the hemoglobin A1c testing devices market during the forecast period.

Segmentation

Haemoglobin A1c Testing Devices Industry Developments

• In March 2019, Beckmann Coulter launched Automated Microplate System which helps in more accurate diabetes diagnosis.


• In June 2016, Randox Laboratories launched Acusera Liquid HbA1c Control with an aim to reduce sample preparation time and is cost effective.